NASDAQ:ANGN

Angion Biomedica Stock Forecast, Price & News

$20.90

+0.98 (+4.92 %)

(As of 03/2/2021 12:00 AM ET)

Add

Compare

Today's Range

$20.00

Now: $20.90▼

$23.24

50-Day Range N/A

52-Week Range

$16.00

Now: $20.90▼

$26.30

Volume469,941 shs

Average Volume220,284 shs

Market Capitalization$600.27 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3777, a hepatocyte growth factor mimetic for acute kidney injury, acute lung injury, acute respiratory distress syndrome, central nervous system injuries, and heart injuries. It also develops products, such as ANG-3070 tyrosine kinase inhibitor and rho kinase 2 inhibitor for fibrotic diseases; and CYP11B2, an aldosterone synthase inhibitor for aldosterone-related fibrotic diseases. The company was founded in 1998 and is headquartered in Uniondale, New York.

Headlines

Angion Biomedica Corp. Announces Closing of $117 Million Initial Public Offering and Concurrent Private Placement, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 9, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ANGN

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.angion.com

Phone415 655 4899

EmployeesN/A

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares28,721,000

Market Cap$600.27 million

Next Earnings DateN/A

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.00 out of 5 stars

Medical Sector

990th out of 1,968 stocks

Biotechnology Industry

24th out of 124 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Angion Biomedica.

5.0 Community Rank

Outperform Votes
Angion Biomedica has received 4 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Angion Biomedica has received 0 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Angion Biomedica has received 100.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Angion Biomedica and other stocks. Vote “Outperform” if you believe ANGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ANGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Angion Biomedica does not currently pay a dividend.
Dividend Growth
Angion Biomedica does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Angion Biomedica insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,503,282.00 in company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

$20.90

+0.98 (+4.92 %)

(As of 03/2/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ANGN News and Ratings via Email

Sign-up to receive the latest news and ratings for ANGN and its competitors with MarketBeat's FREE daily newsletter.

Angion Biomedica (NASDAQ:ANGN) Frequently Asked Questions

Is Angion Biomedica a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Angion Biomedica in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Angion Biomedica stock.
View analyst ratings for Angion Biomedica or view top-rated stocks.

What stocks does MarketBeat like better than Angion Biomedica?

Wall Street analysts have given Angion Biomedica a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Angion Biomedica wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Angion Biomedica's key executives?

Angion Biomedica's management team includes the following people:

Dr. Itzhak D. Goldberg, Exec. Chairman & Chief Scientific Officer (Age 72, Pay $179.7k)
Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D., Pres, CEO & Director (Age 49)
Mr. Gregory S. Curhan, Interim Chief Financial Officer (Age 59)
Ms. Jennifer J. Rhodes J.D., Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 51)
Dr. John F. Neylan, Sr. VP & Chief Medical Officer (Age 68)
Bruce Rich, Assistant Sec.

Who are some of Angion Biomedica's key competitors?

Some companies that are related to Angion Biomedica include Cullinan Management (CGEM), Silverback Therapeutics (SBTX), BioAtla (BCAB), Gracell Biotechnologies (GRCL), iTeos Therapeutics (ITOS), Vor Biopharma (VOR), Nurix Therapeutics (NRIX), Kinnate Biopharma (KNTE), Trillium Therapeutics Inc. (TRIL.TO) (TRIL), Pharvaris (PHVS), Concordia International (CXR), PureTech Health (PRTC), 4D Molecular Therapeutics (FDMT), Sigilon Therapeutics (SGTX) and Pharming Group (PHAR).
View all of ANGN's competitors.

When did Angion Biomedica IPO?

(ANGN) raised $75 million in an IPO on Friday, February 5th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Stifel acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC and Oppenheimer & Co. were co-managers.

What is Angion Biomedica's stock symbol?

Angion Biomedica trades on the NASDAQ under the ticker symbol "ANGN."

When does Angion Biomedica's quiet period expire?

Angion Biomedica's quiet period expires on Wednesday, March 17th. Angion Biomedica had issued 5,000,000 shares in its IPO on February 5th. The total size of the offering was $80,000,000 based on an initial share price of $16.00. During Angion Biomedica's quiet period, insiders and underwriters that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Angion Biomedica?

Shares of ANGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Angion Biomedica's stock price today?

One share of ANGN stock can currently be purchased for approximately $20.90.

How much money does Angion Biomedica make?

Angion Biomedica has a market capitalization of $600.27 million.

What is Angion Biomedica's official website?

The official website for Angion Biomedica is www.angion.com.

How can I contact Angion Biomedica?

The company can be reached via phone at 415 655 4899.

This page was last updated on 3/2/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here